XML 35 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Balance Sheets - Entity [Domain] - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 107,187 $ 120,841
Receivables from collaboration 4,748 50,436
Inventory 19,816 9,670
Prepaid expenses and other current assets 14,076 20,206
Total current assets 145,827 201,153
Property and equipment - net 193,868 192,127
Deferred product costs from collaboration 10,831  
Other assets 2,025 1,159
Total assets 352,551 394,439
Current liabilities:    
Accounts payable 5,190 7,394
Accrued expenses and other current liabilities 13,930 26,206
Facility financing obligation 73,757 72,995
Senior convertible notes-current 64,123 99,355
Deferred product sales from collaboration 13,404 436
Deferred payments from collaboration 171,850 196,967
Total current liabilities 342,254 403,353
Note payable to principal stockholder 49,521 49,521
Sanofi loan facility and loss share obligation 28,415 3,034
Senior convertible notes-long term 35,713  
Other liabilities 12,123 12,301
Total liabilities $ 468,026 $ 468,209
Commitments and contingencies    
Stockholders' deficit:    
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2015 and December 31, 2014    
Common stock, $0.01 par value - 550,000,000 shares authorized at June 30, 2015 and December 31, 2014; 412,316,619 and 406,059,089 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively $ 4,121 $ 4,061
Additional paid-in capital 2,434,777 2,416,967
Accumulated other comprehensive loss (20) (14)
Accumulated deficit (2,554,353) (2,494,784)
Total stockholders' deficit (115,475) (73,770)
Total $ 352,551 $ 394,439